Lowenstein Sandler LLP acted as US counsel Edesa Biotech, Inc., Fasken Martineau DuMoulin, LLP, Canadian local counsel for the Company, Fenwick & West LLP, intellectual property...
Edesa Biotech Closes $25 Million Public Offering of Shares and Warrants
uniQure Completes $259 Million Public Offering of Ordinary Shares
Morgan, Lewis & Bockius LLP, NautaDutilh N.V., Van Campen Liem, Nederlandsch Octrooibureau, and Clark & Elbing, LLP have advised uniQure. Mintz has advised the underwriters. uniQure...
NervGen Pharma Completes $60 Million Public Offering
Joseph Garcia from Blake, Cassels & Graydon LLP has advised NervGen Pharma. Mintz has advised the underwriters. NervGen Pharma has completed a public offering valued at...
Assembly Biosciences Completes $115 Million Registered Offering of Common Stock and Pre-Funded Warrants
Skadden has advised Assembly Biosciences. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo has advised the underwriters. Assembly Biosciences, Inc. has announced the closing of its underwritten...
InflaRx Prices $150 Million Public Offering of Ordinary Shares
Kirkland & Ellis has advised InflaRx. Mintz has advised the underwriters. InflaRx N.V., a biopharmaceutical company focused on anti-inflammatory therapeutics, has announced the pricing of its...
Avalo Therapeutics Launches $430 Million Public Offering of Common Stock and Warrants
Goodwin Procter LLP has advised Avalo Therapeutics. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. has advised the underwriters. Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a...
Potentia Closes $65 Billion Heartland Industrial Park Investment in Indiana
Mintz has advised Potentia Inc. on the deal. Potentia Inc., a major developer of large-scale technology and energy infrastructure, has announced the closing of its investment...
SAB Biotherapeutics Completes $85 Million Public Offering
Dentons has advised SAB Biotherapeutics, Inc. Mintz has advised the underwriters. SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin...
Larimar Therapeutics Launches $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Goodwin Procter LLP has advised Larimar Therapeutics, Inc., and Mintz has advised the underwriters. Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on complex rare diseases,...
Eupraxia Pharmaceuticals Closes US$63.2 Million Public Offering
Mintz and Stikeman Elliott LLP have advised the underwriters. Troutman Pepper and Blake, Cassels & Graydon LLP have advised Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals Inc., a clinical-stage...
Satellos Bioscience Completes US$57.2 Million Cross-Border Public Offering and Nasdaq Listing
Mintz has advised Satellos Bioscience Inc. Latham & Watkins has represented the underwriters. Satellos Bioscience Inc., a clinical-stage biotechnology company, has completed a US$57.2 million underwritten...
Fulcrum Therapeutics Prices $175 Million Public Offering of Stock and Pre-Funded Warrants
Goodwin Procter LLP has advised Fulcrum Therapeutics. Mintz has advised the underwriters. Fulcrum Therapeutics, Inc. (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced the pricing...